<DOC>
	<DOCNO>NCT00731861</DOCNO>
	<brief_summary>This study evaluate PTK787 , new oral drug stop blood vessel development , combination Paclitaxel patient advance solid tumor .</brief_summary>
	<brief_title>Phase I , Pharmacokinetic , Pharmacodynamic Trial PTK787 Paclitaxel Combination Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Adult patient histologically confirm malignancy unresponsive curative therapy conventional therapy exist ECOG Performance Status 02 Measurable evaluable disease Laboratory value within protocol limit within 2 week prior registration Life expectancy ≥ 12 week Patient guardian must write informed consent obtain accord local guideline Women childbearing potential ( nonsterile ) must use appropriate barrier contraception duration study ( negative pregnancy test require baseline ) . Oral contraceptive acceptable form contraception Patients may receive prior standard taxane therapy , never progress taxanebased therapy . History presence central nervous system ( CNS ) disease ( i.e. , primary brain tumor , malignant seizure , CNS metastases carcinomatous meningitis ) . Prior chemotherapy ≤ 3 week prior registration . Patients must recover therapyrelated toxicity Prior biologic immunotherapy ≤ 2 week prior registration . Patients must recover therapyrelated toxicity Prior full pelvic field radiotherapy ≤ 4 week limited field radiotherapy ≤ 2 week prior randomization . Major surgery ( i.e. , laparotomy ) ≤ 4 week prior randomization . Minor surgery ≤ 2 week prior randomization . Patients receive investigational drug ≤ 4 week prior registration Prior therapy antiVEGF agent Peripheral neuropathy functional impairment ≥ CTC grade 2 neuropathy , regardless causality Pleural effusion ascites cause respiratory compromise ( ≥ CTC grade 2 dyspnea ) Female patient pregnant breast feeding , adult reproductive potential employ effective method birth control . Patient agree avoid grapefruit ( juice fruit ) Any follow concurrent severe and/or uncontrolled medical condition could compromise participation study : Uncontrolled high blood pressure , history labile hypertension , history poor compliance antihypertensive regimen Unstable angina pectoris Congestive heart failure great NYHA classification ≥ Grade 1 ( control medication ) Myocardial infarction ≤ 6 month prior registration and/or randomization Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes discretion investigator Active uncontrolled infection require intravenous antibiotic Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Patients risk QT prolongation patient congenital long QT syndrome long QTc baseline ( i.e . QTc great 450 msec male , great 470 msec female ) exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>